ESSA Pharma amends agreement with XenoTherapeutics, lowers payout

ESSA Pharma Inc. has amended its business combination agreement with XenoTherapeutics, significantly reducing the cash payment to shareholders at closing to $0.12 per share from an originally estimated $1.91 per share, citing potential liabilities and revised cash balances. This revised structure follows an earlier $1.69 per share distribution and now includes a contingent value right (CVR) potentially worth up to $0.14 per share. The special shareholder meeting to approve the transaction has been adjourned to October 3.

Analysis

ESSA Pharma Inc. (EPIX) has materially and negatively revised its business combination agreement with XenoTherapeutics, signaling a significant deterioration in expected shareholder value. The cash payment at closing has been reduced by over 93% to approximately $0.12 per share from the originally estimated $1.91. This amendment follows a prior distribution of approximately $1.69 per share in August, but the new structure introduces significant uncertainty. Shareholders will now receive a non-transferable contingent value right (CVR) worth up to $0.14, with its final value dependent on the outcome of undisclosed "potential liabilities" and associated expenses. This change, which prompted the adjournment of the special shareholder meeting to October 3, suggests that unforeseen costs or a lower-than-expected cash balance have impacted the final stages of the company's winding-up process. Despite the stock's 73% decline over the past year and a market capitalization of just $9.76 million, InvestingPro data notes a high current ratio of 69.07, indicating substantial short-term liquidity, likely comprised of the remaining cash held for transaction-related expenses and distributions.

Key Decisions for Investors

• Investors must recalibrate their valuation based on the revised deal terms, which drastically reduce the guaranteed cash payout to just $0.12 per share plus a highly uncertain CVR.
• The primary focus for realizing further value is now the CVR's outcome, which is tied to 'potential liabilities'; therefore, any company disclosures regarding the nature and magnitude of these liabilities ahead of the October 3rd meeting are critical to monitor.
• Given the stock price of $0.21 against a guaranteed $0.12 and a maximum potential total of $0.26, holding or buying the stock is a high-risk special situation play on the CVR's realization, which appears heavily discounted by the market due to its contingent nature.